It is also about blood pressure, inflammation, kidney protection, fatty liver disease, cardiovascular risk, sleep, mobility, and overall metabolic health
Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis
GLP-1 Rebound Prevention: How to Keep the Weight Off After the Needle Worried about weight regain after stopping GLP-1s like Ozempic or Wegovy
The detailed results were established in the Supplementary Materials
Mroz, P
In the STEP 3 trial of semaglutide combined with intensive lifestyle intervention (30 counseling visits across 68 weeks, including nutrition, physical activity, and other behavioral strategies, plus 8 initial weeks of meal replacements with liquid shakes, meal bars, or portion-controlled meals), individuals experienced a 16 % reduction from baseline in body weight (versus 5.7 % with intensive lifestyle intervention alone) [169]